Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human papillomavirus 9-valent vaccine (Merck & Co.)
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intralesional
01
Overview
Gardasil 9 is a non-infectious recombinant nonavalent vaccine designed to protect against nine types of human papillomavirus (HPV). It is composed of purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. These VLPs are produced via recombinant *Saccharomyces cerevisiae* fermentation and are adsorbed onto an amorphous aluminum hydroxyphosphate sulfate (AAHS) adjuvant. The vaccine is primarily indicated for the prophylactic prevention of cervical, vulvar, vaginal, anal, and oropharyngeal cancers, as well as associated precancerous lesions and genital warts (condylomata acuminata) caused by the covered HPV types. While standard administration is intramuscular, clinical research is also exploring its therapeutic potential through intralesional injection for the treatment of existing genital warts.
- Brand names
- Gardasil 9Gardasil9Gardasil-9
- Other names
- 9vHPVnonavalent human papillomavirus vaccineHPV 9-valent vaccineHPV9-valent vaccineHPV-9-valent vaccinehuman papillomavirus 9-valent vaccine, recombinant
02
Targets
HPV L1 (Human papillomavirus L1 capsid protein)
Beyond the preview
Go deeper on human papillomavirus 9-valent vaccine (Merck & Co.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human papillomavirus 9-valent vaccine (Merck & Co.).